Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trio Of Hikma Launches Includes New Icosapent Strength

Also Launches Cefazolin And Labetalol Injectables In Unique Presentations

Executive Summary

Hikma has launched three new generics in quick succession, including a new strength of its icosapent ethyl capsules that rival Vascepa, as well as unique presentations of its cefazolin and labetalol injectables.

You may also be interested in...



Hikma Differentiates With Succinylcholine Chloride PFS

Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.

Hikma Triumphs As Vascepa Induced-Infringement Case Dismissed

An attack on Hikma’s skinny-label generic version of Vascepa by originator Amarin, claiming induced infringement of patents protecting a cardiovascular indication, has been dismissed in the US.

Hikma Has A First With Labetalol Launch In US

Hikma says it is breaking new ground in the US with a ready-to-use presentation of labetalol. Meanwhile, the company has also added hydralazine to its list of recent injectables launches.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel